Grants & Awards

The EUropean Federation for CAncer IMages (EUCAIM) project originates from an unprecedented body of work and expertise of the “AI for Health Imaging” Network (AI4HI), which consists of 86 affiliated institutions from 20 countries involved in 5 large EU-funded projects on big data and AI in cancer imaging (CHAIMELEON, EUCANIMAGE, INCISIVE, ProCancer-I, PRIMAGE; coordinated by HULAFE, UB, MAG, FORTH and HULAFE, respectively). This network will bring information from more than 100.000 patients with cancer. The AI4HI Network has been organised into 8 working groups (Ethical and legal issues, Metadata interoperability, Data storage and management, Data annotation, AI development, AI validation, Clinical Working Group and Outreach Working Group).

Commited patient data: 100.000.

Amount awarded to Quibim: 1.475.682,48€.

More info.

EUCAIM is co-funded by the European Union under Grant Agreement number 1011100633.

CHAIMELEON aims to set up a structured repository for health imaging data to be openly reused in AI experimentation for cancer management. An EU-wide repository will be built as a distributed infrastructure in full compliance with legal and ethics regulations in the involved countries. It will build on partner ́s experience (e.g. PRIMAGE repository for paediatric cancer and the Euro-BioImaging node for Valencia population, by HULAFE; the Radiomics Imaging Archive by Maastricht University; the national repository DRIM AI France, the Oncology imaging biobank by Pisa University). Clinical partners and external collaborators will populate the Repository with multimodality (MR, CT, PET/CT) imaging and related clinical data for historic and newly diagnosed lung, prostate and colorectal cancer patients.

Commited patient data: 39.000.

Amount awarded to Quibim: 458.750€.

More info.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 952172.

The ProCAncer-I project brings together 20 partners, including PCa centers of reference, world leaders in AI and innovative SMEs, with recognized expertise in their respective domains, with the objective to design, develop and sustain a cloud based, secure European Image Infrastructure with tools and services for data handling. The platform hosts the largest collection of PCa multi-parametric (mp)MRI, anonymized image data worldwide (>17,000 cases), based on data donorship, in line with EU legislation (GDPR). Robust AI models are developed, based on novel ensemble learning methodologies, leading to vendor-specific and neutral AI models for addressing 8 PCa clinical scenarios.

Commited patient data: 17.000.

Amount awarded to Quibim: 400.000€.

More info.

ProCAncer-I has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 952159.

PRIMAGE – ENDED – proposes a cloud-based platform to support decision making in the clinical management of malignant solid tumours, offering predictive tools to assist diagnosis, prognosis, therapies choice and treatment follow up, based on the use of novel imaging biomarkers, in-silico tumour growth simulation, advanced visualisation of predictions with weighted confidence scores and machine-learning based translation of this knowledge into predictors for the most relevant, disease-specific, Clinical End Points.

Commited patient data: 3.300.

Amount awarded to Quibim: 919.063,85€.

More info.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 826494.

Chronic pain (CP) is the leading cause of disability, and is strongly associated with fatigue, anxiety and depression ─ also major contributors to disability, and with cardiovascular disease (CVD) and mortality. Twin studies indicate that these associations are a consequence of common causal mechanisms. The main objective of this PainFACT is to identify these mechanisms. Using hypothesis-free genomic, proteomic and metabolomics discovery in available human studies, as well as mining of existing data from mice, we aim to identify biomarkers that are associated across conditions.

Commited patient data: 9.850.

Amount awarded to Quibim: 250.392,5€.

More info.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 848099.

The aim of the ProCanAid project is to develop a computational tool to create a 4D digital twin of the entire prostate of a patient. Novel AI-based magnetic resonance imaging segmentation algorithms will be applied to extract not only patient-specific prostate anatomy (transitional zone, peripheral zone, seminal vesicles, and neurovascular bundle) but also to detect PCa. The digital twin will incorporate in silico models considering the behavior of cells and tissues, to predict the effects of different types of oncological treatments not only on the tumor but also on the entire prostate, as well as to predict the efficacy of these treatments and the possible evolution of the disease. Quibim leads this project as the coordinator entity.

Commited patient data: 500.

Amount awarded to Quibim: 791.954,6€.

More info.

Project PLEC2021-007709 funded by MCIN/AEI/10.13039/501100011033 and by Unión Europea NExtGenerationEU/PRTR

The main objective of the DIPCAN Project for Digitalization and Comprehensive Management of Personalized Medicine in CANcer (MIA.2021.M02.0006) is to develop an algorithm based on artificial intelligence methods that allows to guide and objectively help making decisions regarding the clinical management of the patient. The objectives of the DIPCAN project they also include the effective prediction of tumor genetics, as well as the risk of a certain type of metastasis. In order to carry out, interdisciplinary and coordinated action and integrated analysis of the phenotypic / clinical, pathological, radiomic and genetic data of patients with metastatic cancer will be necessary.

Commited patient data: 2.000.

Amount awarded to Quibim: 674.745,24€.

More info.

RadioVal is the first multi-centre, multi-continental and multi-faceted clinical validation of radiomics-driven estimation of NAC response in breast cancer. The project builds on the repositories, tools and results of five EU-funded projects from the AI for Health Imaging (AI4HI) Network. To test applicability as well as transferability, the validation with take place in eight clinical centres from three high-income EU countries (Sweden, Austria, Spain), two emerging EU countries (Poland, Croatia), and three countries from South America (Argentina), North Africa (Egypt) and Eurasia (Turkey). RadioVal will develop a comprehensive and standardised methodological framework for multi-faceted radiomics evaluation based on the FUTURE-AI Guidelines, to assess Fairness, Universality, Traceability, Usability, Robustness and Explainability. Furthermore, the project will introduce new tools to enable transparent and continuous evaluation and monitoring of the radiomics tools over time.

Commited patient data: >6.000.

Amount awarded to Quibim: 412.500€.

More info.

This work received funding from the European Union’s Horizon Europe research and innovation programme under Grant Agreement No. 101057699 (RadioVal project).

The FLUTE project will advance and scale up data-driven healthcare by developing novel methods for privacy-preserving cross-border utilization of data hubs. Advanced research will be performed to push the performance envelope of secure multi-party computation in Federated Learning, including the associated AI models and secure execution environments. The technical innovations will be integrated in a privacy-enforcing platform that will provide innovators with a provenly secure environment for federated healthcare AI solution development, testing and deployment, including the integration of real world health data from the data hubs and the generation and utilization of synthetic data. To maximize the impact, adoption and replicability of the results, the project will contribute to the global HL7 FHIR standard development, and create novel guidelines for GDPR-compliant cross-border Federated Learning in healthcare.

Commited patient data: 6.000 (to be finally determined).

Amount awarded to Quibim: 530.000€.

More info.

This project has been funded by the European Union under Grant Agreement number 101095382.

QP-Breast^®: Development of a tool based on radiomics and artificial intelligence in MRI images to aid diagnosis and non-invasive tumour characterisation of breast cancer patients for a personalised therapeutic approach.

The QP-Breast® project, funded by the ‘Consolidation of the Business Value Chain’ grant from IVACE+i, aims to revolutionise the diagnosis and treatment of breast cancer using advanced artificial intelligence (AI) techniques and magnetic resonance imaging (MRI). Backed by Quibim’s extensive experience in the development of radiomic tools, the project will collect images and clinical information from approximately 1000 patients with the aim of implementing an automatic segmentation method for breast lesions and other key regions, such as breast tissue and the nipple. It will also include a data harmonisation layer to ensure the construction of models that are generalisable and applicable in a variety of clinical settings. Advanced predictive models will be developed for tumour characterisation (HER2 receptors and ER/PR hormone status), risk stratification of adverse outcomes and prediction of response to neoadjuvant treatment. This project aims to provide more accurate diagnostics, promote personalisation of treatments and set a new standard in comprehensive breast cancer care.

Commited patient data: 1.000 patients approximately (figure subject to change).

Amount awarded to Quibim: 180.108,19€.

More info